World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers © All Rights Reserved Available online at: http://www.wjpsonline.com/ Case Study



METRONIDAZOLE INDUCED SEIZURES

Mir S Adil^{*1}, Azizullah G², M.d Amer K¹, M Nematullah K¹, M Aamer K¹, Ihtisham S¹

¹Pharm.D, Deccan School of Pharmacy, Hyderabad -01, Andhra Pradesh, India ²M.Pharm, Deccan School of Pharmacy, Hyderabad -01, Andhra Pradesh, India

Received: 13-10-2013 / Revised: 21-10-2013 / Accepted: 09-11-2013

ABSTRACT

This is a case report of a four year old female patient who was admitted to pediatrics ward at Owaisi Hospital and Research Centre with chief complaints of abdominal pain and burning sensation while micturition since 2 days, associated with frequent straw colored urination and nausea. The condition was diagnosed as Cystitis, for which antibiotics were started. Three days post administration of Metronidazole, seizures were experienced by the patient. This ADR has scored 6 on naranjo algorithm, which indicates the reaction as probable. This is a rare case of metronidazole induced seizures in a pediatric patient. The reason behind the event could be the dose of metronidazole, which was slightly higher than the calculated dose according to the weight of the patient.

Keywords: metronidazole, seizure, ADR, drug induced convulsions

INTRODUCTION

A seizure is a paroxysmal clinical event of the central nervous system, characterized by an abnormal electrical discharge and associated with a change in the usual functioning. A seizure occurs when there is a sudden imbalance between the excitatory and inhibitory inputs to a network of neurons in the cerebral cortex, so that there is overall excessive excitability.[1] Almost every drug and toxin can produce seizure. Some drugs such as tramadol and TCA cause seizure more commonly. Withdrawal from opioids, ethanol, and some benzodiazepines and phenobarbitals may cause late seizure. Standard treatment in seizure due to unknown toxin is done with a benzodiazepine firstly and then phenobarbital or phenytoin. There are also special treatments, for example, pyridoxine in isoniazid-induced seizure, naloxone in propoxyphene-induced seizure, and glucose in seizure due to hypoglycemia.[2] Metronidazole is a 5-nitroimidazole (as shown in figure 1) with potent activity against anaerobic bacteria and several protozoa, including Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis and Balantidium coli. This is the drug of choice for giardiasis and initial treatment of invasive amoebiasis.[3]

Metronidazole is classified in the WHO Essential Medicines List as antiamoebic, antigiardiasis, and antibacterial.[4] It is used in combination with other antibiotics and either bismuth compounds or proton pump inhibitors for treatment of peptic ulcer disease caused by Helicobacter pylori.[5] Metronidazole is, in general, very well tolerated, has a wide therapeutic index, and its serum and tissue concentrations do not require routine determination.[5,6] The common side effects include mild abdominal pain, headache, nausea and a persistent metallic taste. Other serious and rare side effects include pseudomembranous colitis, seizures and encephalopathy.[3] Less frequent untoward effects in the digestive tract include an unpleasant metallic taste and vomiting.[7,8] Metronidazole is absorbed rapidly with a bioavailability (BA) of higher than 90% and approaching toward 100%.[8,9] According to Simms-Cendan, metronidazole is passively transported through mammalian cells.[5] Metronidazole is widely distributed and appears in most body tissues and fluids. Less than 20% of the circulating metronidazole is bound to plasma proteins. The distribution volume ranges from 0.51 to 1.1 L/kg. Metronidazole is metabolized in the liver.[8-10]

Convulsive episodes are associated with the use of a number of antimicrobial agents. Although seizures may be a feature of the disease being treated, antibiotics should be considered possible

*Corresponding Author Address: Dr. Mir Shoeb Ulla Adil, PharmD, Deccan School of Pharmacy, Darus-salam, Nampally, Hyderabad – 01, A.P. India; Email: iampharmd@rediff.com

Mir S Adil *et al.*, World J Pharm Sci 2014; 2(1): 108-111 v if suggested by DISCUSSION

causes of seizures, particularly if suggested by temporal relationships between seizure activity and drug administration. The astute clinician should be aware of the clinical settings in which antibioticinduced seizures occur, be familiar with likely agents and their mechanisms of toxicity, and be prepared to institute appropriate management directed at this adverse effect of antimicrobial therapy.[11] Metronidazole in high cumulative doses has been associated with convulsions.[12]

Convulsions induced by shortterm metronidazole therapy used in conventional doses for Clostridium difficile colitis in an elderly patient with Chronic Renal Failure was also reported.[13] The estimation of the probability that a drug caused an adverse clinical event is usually based on clinical judgment. Lack of a method for establishing causality generates large betweenraters and within-raters variability in assessment. There are several methods to assess causality. which includes WHO probability scale, Naranjo's scale, Karch & Lasagna scale, Spanish quantitative imputation scale, Kramer's scale, Jones scale, European ABO system and Bayesian system.[14]

CASE REPORT

A four year old female patient was admitted to pediatrics ward at Owaisi Hospital and Research Centre with chief complaints of abdominal pain and burning sensation while micturition since 2 days, associated with frequent straw colored urination and nausea. At the time of admission, the patient's blood pressure, pulse rate and temperature were normal and the treatment was started with antibiotics as given in table 1. CBP, CUE and urine dipstick test were advised to the patient. On the second day, test reports were obtained which are given in table 2, 3 & 4. Pain and abdominal tenderness were observed. The condition was diagnosed as Cystitis, same therapy was continued on the day two. An episode of seizure was experienced on the third day. Vitals were stable with persistent abdominal pain and tenderness. Inj. Eptoin (Phenytoin) was given to prevent further episodes of convulsions and Tab. Cyclospasmol was added in the therapy to lower the pain. On the fourth day, Metronidazole was suspected to be the cause of Seizures. Hence, it was replaced by Ampicillin to treat the infection. On the next day, pain was slightly decreased and the same treatment was continued as that of day four. There was much improvement in the symptoms on the fifth day as a result, the patient was discharged.

Metronidazole is generally considered to be a safe drug with less adverse effects. This is a a rare case of metronidazole induced seizures in a pediatric patient. The reason behind the event could be the dose of metronidazole, which was slight higher than the calculated dose according to the weight of the patient. The present adverse drug reaction has scored 6 on Naranjo Algorithm, a scale for assessing causality, which categorises the ADR as "Probable" as given in table 5.

Surviving with Seizures: Children with epilepsy often need to make lifestyle changes to minimize the frequency of seizures and possible dangers associated with seizures. Parents should teach their child to avoid biking, skating, and skateboarding on streets with heavy traffic. All children need to wear protective gear, including a helmet, during these activities. Activities at heights (eg, climbing a tree or rope) should be avoided to prevent serious falls if the child has a seizure while climbing. Always children should be supervised around water, Children with epilepsy should wear a medical identification bracelet or necklace at all times. If a seizure occurs and the child is unable to explain their condition, this will help responders give the proper care as quickly as possible. Children should be encouraged to sleep well and take medications on time.

CONCLUSION

Metronidazole induced seizures is a rare adverse drug reaction, the present case report can elevate the evidence against metronidazole for causing Seizures. Further studies can be carried out to establish a link between this drug and the disease. If possible, Metronidazole should be avoided in the patients with past history of convulsions.

CONFLICT OF INTEREST

Authors state that there is no conflict of interest.

ACKNOWLEDGEMENT

Most importantly we are thankful to the Almighty who is the lord of the worlds'. We take this opportunity to express our deep sense of gratitude, respect to Dr. S.A. Azeez Basha, Principal, Deccan School of Pharmacy, Hyderabad for encouraging us during the work.

Mir S Adil et al., World J Pharm Sci 2014; 2(1): 108-111



Figure 1: Structure of Metronidazole

		Table 1: Therapy			
	Brand name	Generic name	Dose	Route	Frequency
	Inj. C.Tri	Cefuroxime	1gm	iv	BD
	Inj. Metrogyl	Metronidazole	40ml	iv	TID
	Tab. Tyfy	Paracetamol	300mg	oral	TID
	IVF Iso-P Inj. Zofer	Multi-Electrolytes Ondansetron	500ml 2cc	iv iv	TID BD
	Inj. Zoler Inj. Rantac	Ranitidine	200 100	iv	BD BD
	inj. Runde			1 1	
	Parameter	Table 2: C		Norr	nal range
	RBC	<i>Test value</i> $4.4 \times 10^6/\text{mm}^3$		Normal range 3.9 – 5.3	
	Hb	4.4 x 10 /mm 11.9g/dL		11.5 – 15.5	
	PLT	401 x	150 - 450		
	WBC	7.96 x		5 – 15.5	
	Neutrophils	55.9%		23-45	
	Lymphocytes		.4%		5 – 65
	Erythrocytes	4.7%			3 - 6
	Monocytes	2.1%			0-3
	Basophils	0.75%			0 - 1
		Table 3: C	TIF		
	—	<i>Characteristic</i>	Test		
		Color	Straw		
		Transparency	Slight		
		Specific gravity	1.03		
		рН	6.5		
		Albumin	Trace		
		Sugar	Trace		
		Epithelial cells	2-3		
		Pus cells	2 - 3 2 - 4		
		r us cens	2-4		
		Table 4: Bacterial Dipstick Test			
		Dipstick Test			
		Bacteria	Positive		
		presence			
		Table 5: Naranjo Alg	orithm values		
		Score	Type of ADE	2	
		≥ 9	Definite		
	5 - 8		Probable	Probable	
		1 – 4 Po			
		0	Doubtful		

Mir S Adil et al., World J Pharm Sci 2014; 2(1): 108-111

Abbreviation	Full Form	Abbreviation	Full Form					
ADR	Adverse Drug Reaction	mg	Milligram					
BD	Twice a day	ml	Millilitre					
CBP	Complete Blood Picture	PLT	Platelet					
CUE	Complete Urine Examination	RBC	Red Blood Cell					
dL	Decilitre	Tab	Tablet					
gm	Gram	TID	Thrice a day					
Īnj	Injection	WBC	White Blood Cell					
iv	Intravenous	WHO	World Health Organization					

LIST OF ABBREVIATIONS:

REFERENCES

- 1. Mir S Adil et al. Phenytoin Induced Erythematosus Rash in a Diabetic Seizure Patient. Indo-American Journal of Pharm Research 2013:3(9).
- 2. Behnam Behnoush et al. Prevalence and Complications of Drug-induced Seizures in Baharloo Hospital, Tehran, Iran. Iranian Journal of Toxicology Volume 6, No 16, Spring 2012.
- 3. Gupta B S et al. Metronidazole induced neuropathy. Neurol India 2000;48:192.
- 4. World Health Organization (WHO). 2009. WHO Model Lists of Essential Medicines, 16th ed. (accessed November 20, 2009).
- 5. Simms-Cendan JS. Metronidazole. J Infect Dis 3(5):153–156.
- 6. Ralph ED. Clinical pharmacokinetics of Metronidazole. Clin Pharmacokinet 8(1):43-62.
- 7. Troy DB. Remington: The science and practice of pharmacy, 21st ed. Philadelphia, PA.; Lippincott Williams & Wilkins; pp. 1669.
- Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's. The pharmacological basis of therapeutics, 10th ed, New York; McGraw-Hill Medical Publishing Division; pp. 1105–1109.
- Lamp KC et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36(5):353– 373.
- 10. Ralph ED et al. Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother 6(6):691-696.
- 11. Kevin L Wallace. Antibiotic-Induced Convulsions. Critical care clinics, volume 13, issue 4 (741-762).
- 12. Halloran TJ. Convulsions associated with high cumulative doses of metronidazole. Drug Intell Clin Pharm. 1982 May;16(5):409.
- 13. Beloosesky et al. Convulsions induced by metronidazole treatment for Clostridium difficile associated disease in chronic renal
- failure. The American journal of the medical sciences.
- 14. Mir S Adil et al. Ciprofloxacin Induced Systemic Lupus Erythematosus. Indo-American Journal of Pharm Research 2013;3(9).